Flowneuroscience
-65%
est. 2Y upside i
Rank
#979
Sector
Therapeutic Devices
Est. Liquidity
~3Y
Data Quality
Data: MediumFlow Neuroscience operates in a massive, underserved market with a strong regulatory moat as the first FDA-approved at-home brain stimulation device for depression.
Last updated: March 10, 2026
Flow Neuroscience successfully scales commercialization post-FDA approval, securing significant reimbursement and expanding into new indications like anxiety. Revenue reaches $100M+ by 2028, justifying a $480M-$500M+ valuation at 5-6x revenue, attracting a strategic acquisition by a major medical device firm.
Flow Neuroscience achieves steady adoption of its at-home depression treatment, reaching $40M-$50M in revenue by 2028. The company maintains its niche against office-based TMS and digital therapy competitors, leading to an acquisition at a $220M-$250M valuation.
Commercialization efforts falter due to slow reimbursement adoption and aggressive entry from an incumbent medical device company with a competing at-home solution. Revenue growth stalls, leading to a down round or distressed acquisition at a $50M-$60M valuation, significantly impacting common stock value due to liquidation preferences.
Preference Stack Risk
moderateInvestors hold $27M in liquidation preferences, meaning common stock holders would only see returns after this amount is paid out in an exit.
Dilution Risk
highAs the company is not yet profitable and requires significant capital for commercialization, further funding rounds are likely, leading to additional dilution for existing equity holders.
Secondary Liquidity
noneNo active secondary market or tender offers are indicated, meaning liquidity for employee equity is tied to a future IPO or acquisition.
Questions to Ask at the Interview
Strategic questions based on Flowneuroscience's data — designed to show you've done your homework.
- 1
“Given the recent FDA approval for the at-home device, what are the key strategies and challenges for securing widespread insurance reimbursement, especially compared to established office-based TMS treatments from companies like Neuronetics?”
- 2
“Flow Neuroscience operates in two market segments: at-home brain stimulation and digital mental health. How does the company plan to leverage its unique hardware advantage to differentiate its app-based therapy from the broader digital mental health solutions market, which includes well-funded competitors like Mindler?”
- 3
“With $27M in total funding and not yet profitable, what is the company's projected runway, and what milestones are critical to achieve before the next funding round or a potential liquidity event for employees?”
Community
Valuation Sentiment
Our model estimates -65% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.